What do we do?

AtCentro Ararat, Inc., research is the driving force behind our passion for innovation and our commitment to the health and well-being of our patients. With more than 20 years of experience, we have specialized in cutting-edge clinical trials that evaluate treatments and therapies for diseases such as HIV, hepatitis C, and hyperlipidemia, among others. We work closely with both local and national academic institutions to identify and address the health needs of people in Puerto Rico.

Through this collaboration, we have developed innovative programs that address these needs, and we have pioneered the implementation of Special Programs of National Significance (SPNS), establishing ourselves as a leading center for quality and reliability. These programs not only benefit our community but also serve as models for other health centers across the island.

Every step we take reinforces our commitment to transforming health care through research, the application of up-to-date knowledge, and, above all, our commitment to improving the lives of every patient we care for.

Why is clinical research important?

  • Medical Advances: Clinical research enables the development of new treatments, medications, and therapies.
  • Safety and Efficacy: They ensure that treatments are safe and effective before they are approved.
  • Improved Care: They contribute to more advanced and personalized medical care.
  • Knowledge development: They generate scientific evidence that guides medical and health policy decisions.
  • Access: They promote accessible and effective treatments for different communities.

Principal Investigators:

  • Iván Meléndez-Rivera, MD, FAAFP
  • Maribel Acevedo-Quiñones, MD
  • Iván Báez-Santos, PsyD

Sub-Researchers:

  • Julio Bacó-Dávila, MD
  • Nadja Diaz-Báez, MD
  • Juan Ramirez-Malave, MD
  • Alejandra Velez-Rivera, MD

For more information about clinical trials or potential collaborations, please email us at: research@centroararat.org

Current studies

PURPOSE 2: Study of Lenacapavir for pre-exposure prophylaxis against HIV in people at risk of HIV infection.

  • Active, not recruiting

Wonders 1: A Studyof Weekly Oral GS-1720 and GS-4182 Versus Biktarvy in People with HIV-1 Who Are Virologically Suppressed.

  • Active, not recruiting

Current collaborations

  • “Proyecto Cura”Mobile Tele-Hepatitis C Community Care for People Who Inject Drugs in Puerto Rico –City University of New York (CUNY) Graduate School of Public Health and Health Policy
  • Optimizing PrEP Uptake Among Latin MSM in Puerto Rico: A Comparative Effectiveness Study– University of Puerto Rico, Medical Sciences Campus (UPR-RCM)
  • Clinical Use of Doxycycline as Post-Exposure Prophylaxis (Doxy-PEP) for Sexually Transmitted Infections in Puerto Rico: A Retrospective Evaluation –Barry and Judy Silverman College of Pharmacy, Nova Southeastern University (NSU)
  • Effects of Environmental and Infrastructure Disruptions on Health Outcomes in People with HIV: A Cross-Sectional Study –Yale University School of Nursing
#thegov_search_6a66159d4df30:hover { color: rgba(255,255,255,1) !important; }